Eloxx Pharmaceuticals Inc (ELOX) @ NASDAQ
Printed Monday, 6 July '26 07:17 MST
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribonucleic acid modulating drug candidates for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial that focuses on the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company was incorporated in 2013 and is headquartered in Waltham, Massachusetts.
Biotechnology Pharmaceuticals, Biotechnology & Life Sciences Common Stock β -168027.7
| Date | Name (*Public) | Description | Symbol | Type | Size | Action |
|---|
| Date | Value | Error | Logarithmic | Error | Model (*Public) |
|---|
+$0.465 (3.84%) on Thursday, 2 July 2026, Marketcap $43.18 M
| Date | Value | Δ | Open | Close | Low | High | Adjusted | Volume | Δ |
|---|
| Name | Version (*Public) | Indicator % | Auto | Description | Symbol | Company Name | Forecasts | Buy / Sell | Action |
|---|
| Opened (Closed) | Expires | Symbol | Company Name | Name (*Public) | Size | Contract Symbol | Open P/L | Close P/L | Total P/L | ROI | DTE | DIT | Delta | Action |
|---|
| Details | Best Trend by Hindsight | Forecast | Profit or Loss | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Date (*Public) | Symbol | Strategy | Data | Origin | Slope | Sigma | Cor % | Moves | Sigma | Moves | Gain % | Periods | Action |
| Date | Name (*Public) | Description | Price | Quantity | Total | Cost | Type | Symbol | Action |
|---|
| Date | RSI | Stochastic %D | Stochastic %K | MACD | MACD Divergence | MACD Signal | DMI | CCI | Volatility | Bollinger Upper | Bollinger Mid | Bollinger Lower |
|---|
| Date | Name | Description | Type | Symbol | Company Name | Location |
|---|
| Date UTC | Location | Action | Description | Object | Severity | User | Action |
|---|
